One Case of Extremely Severe Thrombocytopenia Caused by Tirofiban Injection

doi:10.19803/j.1672-8629.20240793

Abstract

Abstract: Objective To investigate the clinical characteristics, management strategies and outcomes of extremely severe thrombocytopenia induced by tirofiban. Methods One case of severe thrombocytopenia induced by tirofiban was analyzed, the correlation between thrombocytopenia and tirofiban was studied, and related literature was retrieved before the mechanisms underlying tirofiban-induced thrombocytopenia were investigated. Results Tirofiban was discontinued immediately after detection of the adverse reaction, followed by quick symptomatic treatment. Subsequent blood routine indices returned to normal, clinical parameters were stabilized, and the patient showed favorable recovery with a good prognosis. Conclusion Cases of extremely severe thrombocytopenia caused by tirofiban are relatively rare. Clinical pharmacists’ analysis of the treatment process can facilitate individualized medications in similar cases. It is recommended that clinicians monitor platelet counts while tirofiban is used and remain vigilant against adverse reactions.

Key words: Tirofiban, Injection, Bleeding, Thrombocytopenia, Percutaneous Coronary Interventions, Adverse Drug Reaction

CLC Number:

R972

WANG Yuan, LI Ruoning, GUO Zhanli, ZHANG Lei, LI Jiayuan, DONG Ying, SUN Jianjun. One Case of Extremely Severe Thrombocytopenia Caused by Tirofiban Injection[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 815-818.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240793

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I7/815

References

[1] PIAO B, LI T, ZHONG H, et al.Acute Profound Thrombocytopenia Induced by Tirofiban in Stent Assisted Embolization of Intracranial Ruptured Aneurysm: a Rare Case Report[J]. Heliyon, 2023, 9(4): e14504.
[2] GUO YZ, ZHAO ZW, LI SM, et al.Clinical Efficacy and Safety of Tirofiban Combined with Conventional Dual Antiplatelet Therapy in ACS Patients Undergoing PCI[J]. Scientific Reports. 2021, 11(1): 17144.
[3] YUAN S, OTROCK ZK.Platelet Transfusion: an Update on Indications and Guidelines[J]. Clinics In Laboratory Medicine, 2021, 41(4): 621-634.
[4] TANG X, LI R, ZHANG T.Comparison of Intracoronary Versus Intravenous Tirofiban in Acute ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention[J]. Coronary Artery Disease, 2022, 33(7): 547-552.
[5] KING S, M SHORT, C HARMON. Glycoprotein IIb/IIIa Inhibitors: The Resurgence of Tirofiban[J]. Vascular Pharmacology, 2016, 78: 10-16.
[6] KANG SX, MENG XM, LI J.Effect of Tirofiban Injection on Vascular Endothelial Function, Cardiac Function and Inflammatory Cytokines in Patients with Acute Myocardial Infarction after Emergency Percutaneous Coronary Intervention[J]. Pakistan Journal of Medical Sciences, 2022, 38(1): 9-15.
[7] PENG R, LI F.The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function[J]. Journal of Healthcare Engineering, 2022, 2022: 4708572.
[8] WANG J, D ZOU. Tirofiban-Induced Thrombocytopenia[J]. Annals of Medicine, 2023, 55(1): 2233425.
[9] LIU XL, PENG PA, CHENG YJ.Chinese Expert Consensus on Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Treatment of Coronary Atherosclerotic Heart Disease(2016)[J]. Chinese Journal of Cardiovascular and Pulmonary Diseases, 2016, 35(12): 923-932.
[10] XU D, YANG C, CAO W, et al.Platelet Glycoprotein IIb/IIIa Antagonists in Ischemic Stroke Patients without Endovascular Therapy: a Meta-Analysis[J]. Pharmacotherapy, 2024, 44(8): 675-691.
[11] ASTER RH.Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa Inhibitors[J]. Chest, 2005, 127(2): 53s-59s.
[12] GIORDANO A, D'ANGELILLO A, ROMANO S, et al. Tirofiban Induces VEGF Production and Stimulates Migration and Proliferation of Endothelial Cells[J]. Vascular Pharmacology, 2014, 61(2-3): 63-71.
[13] BOUGIE DW, WILKER PR, WUITSCHICK ED, et al.Acute Thrombocytopenia after Treatment with Tirofiban or Eptifibatide is Associated with Antibodies Specific for Ligand-Occupied GPIIb/IIIa[J]. Blood, 2002, 100(6): 2071-2076
[14] MARINI I, UZUN G, JAMAL K, et al.Treatment of Drug-Induced Immune Thrombocytopenias[J]. Haematologica, 2022, 107(6): 1264-1277.
[15] NURDEN AT, POUJOL C, DURRIEU-JAIS C, et al.Platelet Glycoprotein IIb/IIIa Inhibitors: Basic and Clinical Aspects[J]. Arteriosclerosis Thrombosis Vascular Biology, 1999, 19(12): 2835-2840.
[16] GEORGE JN, ASTER RH.Drug-Induced Thrombocytopenia: Pathogenesis, Evaluation, and Management[J]. Hematology American Society Hematology Education Program, 2009, 1: 153-158.
[17] ESTEVEZ B, SHEN B, DU X.Targeting Integrin and Integrin Signaling in Treating Thrombosis[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35(1): 24-29.
[18] RIKKEN S, VAN 'T HOF AWJ, TEN BERG JM, et al. Critical Analysis of Thrombocytopenia Associated with Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism[J]. Journal of the American Heart Association, 2023, 12(24): e031855.
[19] YI YH, YIN WJ, GU Z C, et al.A Simple Clinical Pre-Procedure Risk Model for Predicting Thrombocytopenia Associated with Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention[J]. Frontiers in Pharmacology, 2018, 9: 1456.
[20] JONES A, SWAN D, LISMAN T, et al.Anticoagulation in Chronic Kidney Disease: Current Status and Future Perspectives[J]. Journal of Thrombosis and Haemostasis, 2024, 22(2): 323-336.
[21] WANG ZM, WANG B, LI YF, et al.Severe Thrombocytopenia Induced by Tirofiban after Percutaneous Coronary Intervention: a Case Report[J]. Journal Medical Case Reports, 2023, 17(1): 430.
[22] SULLIVAN AE, NANNA MG, WANG TY, et al.Bridging Antiplatelet Therapy after Percutaneous Coronary Intervention: JACC Review Topic of the Week[J]. Journal of The American College of Cardiology, 2021, 78(15): 1550-1563.
[23] MUHLESTEIN JB, HACKETT IS, MAY HT, et al.Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry)[J]. The American Journal of Cardiology, 2019, 123(12): 1927-1934.
[24] QIU T, LI C, HUANG L, et al.Tirofiban Combined with Heparin’s Effect and Safety in the Treatment of Mild to Moderate Acute Ischemic Stroke[J]. Neurological Research, 2021, 43(3): 220-224.
[25] KOSTER A, NAGLER M, ERDOES G, et al.Heparin-Induced Thrombocytopenia: Perioperative Diagnosis and Management[J]. Anesthesiology, 2022, 136(2): 336-344.
[26] WANG JX, ZHANG FC.Expert Consensus on the Diagnosis and Treatment of Thrombocytopenia in Chinese Adults[J]. Chinese Journal of Internal Medicine, 2020, 59(7): 498-510.
[27] COLLET JP, THIELE H.Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation and Coexistent Atrial Fibrillation-Dual Versus Triple Antithrombotic Therapy[J]. European Heart Journal, 2021, 42(20): 2020-2021.
[28] WANG HL, AGUILERA C, KNOPF KB, et al.Thrombocytopenia in the Intensive Care Unit[J]. Intensive Care Medicine, 2013, 28(5): 268-280.